ATE383873T1 - Verwendung eines cd40:cd154 bindungs- unterbrechers zur behandlung immunologischer komplikationen des auges - Google Patents

Verwendung eines cd40:cd154 bindungs- unterbrechers zur behandlung immunologischer komplikationen des auges

Info

Publication number
ATE383873T1
ATE383873T1 AT00973678T AT00973678T ATE383873T1 AT E383873 T1 ATE383873 T1 AT E383873T1 AT 00973678 T AT00973678 T AT 00973678T AT 00973678 T AT00973678 T AT 00973678T AT E383873 T1 ATE383873 T1 AT E383873T1
Authority
AT
Austria
Prior art keywords
treatment
ocular
inhibition
resulting
complications
Prior art date
Application number
AT00973678T
Other languages
English (en)
Inventor
M Dana
Akshay Vaishnaw
Linda Burkly
Roy Lobb
Burt Adelman
Original Assignee
Biogen Idec Inc
Schepens Eye Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Schepens Eye Res Inst filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of ATE383873T1 publication Critical patent/ATE383873T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Prostheses (AREA)
AT00973678T 1999-10-22 2000-10-19 Verwendung eines cd40:cd154 bindungs- unterbrechers zur behandlung immunologischer komplikationen des auges ATE383873T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16090999P 1999-10-22 1999-10-22
US19645300P 2000-04-11 2000-04-11
US22949100P 2000-08-31 2000-08-31

Publications (1)

Publication Number Publication Date
ATE383873T1 true ATE383873T1 (de) 2008-02-15

Family

ID=27388532

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00973678T ATE383873T1 (de) 1999-10-22 2000-10-19 Verwendung eines cd40:cd154 bindungs- unterbrechers zur behandlung immunologischer komplikationen des auges

Country Status (10)

Country Link
US (1) US20030027744A1 (de)
EP (1) EP1223981B1 (de)
JP (1) JP2003512439A (de)
AT (1) ATE383873T1 (de)
AU (1) AU784350B2 (de)
CA (1) CA2387889A1 (de)
DE (1) DE60037822D1 (de)
HK (1) HK1049785A1 (de)
NZ (1) NZ518483A (de)
WO (1) WO2001030386A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1294391B1 (de) * 2000-06-09 2012-08-15 Bristol-Myers Squibb Company Wirkstoffkombination zur verhinderung der transplantatabstossung
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
AU2003272471B2 (en) 2002-09-18 2010-10-07 Trustees Of The University Of Pennsylvania Method of inhibiting choroidal neovascularization
CA2539324A1 (en) * 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
US8637070B2 (en) * 2005-02-09 2014-01-28 Santen Pharmaceutical Co., Ltd. Rapamycin formulations and methods of their use
DK2444079T3 (en) * 2005-05-17 2017-01-30 Sarcode Bioscience Inc Compositions and Methods for the Treatment of Eye Diseases
EP2001438A2 (de) 2006-02-09 2008-12-17 Macusight, Inc. Stabile formulierungen sowie verfahren zu ihrer herstellung und verwendung
ES2563288T3 (es) 2006-03-23 2016-03-14 Santen Pharmaceutical Co., Ltd Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
WO2009143141A1 (en) * 2008-05-19 2009-11-26 Case Western Reserve University Method for treating cd40-mediated diseases
WO2010140698A1 (ja) * 2009-06-03 2010-12-09 国立大学法人東北大学 多能性幹細胞からの神経堤細胞群の分化誘導方法
EP3143399A1 (de) 2014-05-12 2017-03-22 Biogen MA Inc. Biomarker zur vorhersage des fortschreitens von lupus und verwendungen davon
KR101752280B1 (ko) 2015-03-31 2017-06-30 서울대학교산학협력단 영장류 cd154에 특이적인 항체 및 이를 생산하는 융합 세포주
EP4054595A4 (de) * 2019-11-07 2023-11-15 Massachusetts Eye and Ear Infirmary Kultivierte autologe limbal-epithelzellen (calec)-transplantation
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2777092A (en) * 1991-10-04 1993-05-03 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Treatment of ocular inflammation by blockage of cell adhesion molecules
US7070777B1 (en) * 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
WO1995024217A1 (en) * 1994-03-08 1995-09-14 Dana-Farber Cancer Institute Methods for modulating t cell unresponsiveness
US6440418B1 (en) * 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
CA2198972A1 (en) * 1996-03-05 1997-09-05 Clyde L. Schultz Contact lens containing a leachable absorbed antibody
KR20000035918A (ko) * 1996-08-28 2000-06-26 데이비드 엠 모이어 1,3-디헤테로시클릭 메탈로프로테아제 저해제
EA002549B1 (ru) * 1997-05-17 2002-06-27 Байоджен, Инк. Применение блокатора связывания cd40:cd154 для предотвращения противоадаптивных иммунных реакций, в частности отторжения трансплантата
US6773916B1 (en) * 1999-01-05 2004-08-10 The Flinders University Of South Australia Agents and methods for treatment and diagnosis of ocular disorders

Also Published As

Publication number Publication date
EP1223981B1 (de) 2008-01-16
DE60037822D1 (de) 2008-03-06
CA2387889A1 (en) 2001-05-03
AU1216401A (en) 2001-05-08
JP2003512439A (ja) 2003-04-02
WO2001030386A1 (en) 2001-05-03
US20030027744A1 (en) 2003-02-06
NZ518483A (en) 2004-03-26
EP1223981A1 (de) 2002-07-24
HK1049785A1 (zh) 2003-05-30
AU784350B2 (en) 2006-03-16

Similar Documents

Publication Publication Date Title
ATE383873T1 (de) Verwendung eines cd40:cd154 bindungs- unterbrechers zur behandlung immunologischer komplikationen des auges
Hori et al. Immunological characteristics of amniotic epithelium
O’Sullivan et al. Ocular mucosal immunity
Duffner et al. Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease
Jang et al. B cells limit repair after ischemic acute kidney injury
Godwin et al. Regeneration, tissue injury and the immune response
Li et al. Deep anterior lamellar keratoplasty using acellular corneal tissue for prevention of allograft rejection in high-risk corneas
Dana Comparison of topical interleukin-1 vs tumor necrosis factor-alpha blockade with corticosteroid therapy on murine corneal inflammation, neovascularization, and transplant survival (an American Ophthalmological Society thesis)
HUP0003392A2 (hu) CD40:CD154 Kötés megszakításának alkalmazása beépülés elleni immunválaszok, különösen graft-kilökődés megakadályozására
Wang et al. Thioredoxin peroxidase secreted by Echinococcus granulosus (sensu stricto) promotes the alternative activation of macrophages via PI3K/AKT/mTOR pathway
Nguyen et al. Anti-IgD antibody attenuates collagen-induced arthritis by selectively depleting mature B-cells and promoting immune tolerance
Droho et al. Monocyte-derived macrophages are necessary for beta-adrenergic receptor-driven choroidal neovascularization inhibition
Denecke et al. Synergistic effects of prolonged warm ischemia and donor age on the immune response following donation after cardiac death kidney transplantation
Sauma et al. Cyclosporine preconditions dendritic cells during differentiation and reduces IL-2 and IL-12 production following activation: a potential tolerogenic effect
Wang et al. Immunogenicity and antigenicity of allogeneic amniotic epithelial transplants grafted to the cornea, conjunctiva, and anterior chamber
Wang et al. Effect of rapamycin and interleukin-2 on regulatory CD4+ CD25+ Foxp3+ T cells in mice after allogenic corneal transplantation
ATE304865T1 (de) Hemmung xenoreaktiver antikörper
Kant et al. Primary vascularization of allografts governs their immunogenicity and susceptibility to tolerogenesis
Lin et al. Optimizing chimerism level through bone marrow transplantation and irradiation to induce long-term tolerance to composite tissue allotransplantation
KR101662720B1 (ko) 각막질환 또는 결막질환의 치료용 조성물
Park et al. Immunosuppressive property of dried human amniotic membrane
Kovalchin et al. In vivo treatment of mice with heat shock protein, gp96, improves survival of skin grafts with minor and major antigenic disparity
Tan et al. Tim-1 blockade with RMT1-10 increases T regulatory cells and prolongs the survival of high-risk corneal allografts in mice
Jager et al. Immunosuppressive properties of cultured human cornea and ciliary body in normal and pathological conditions
Chamond et al. Immunotherapy of Trypanosoma cruzi infections

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties